Abstract
Naturally occurring molecules derived from higher plants, animals, microorganisms and minerals play an important role in the discovery and development of novel therapeutic agents. The identification of molecular targets is of interest to elucidate the mode of action of these compounds, and it may be employed to set up target-based assays and allow structure-activity relationship studies to guide medicinal chemistry efforts toward lead optimization. In recent years, plant-derived natural compounds possessing potential anti-tumor activities have been garnering much interest and efforts are underway to identify their molecular targets. Here, we attempt to summarize the discoveries of several natural compounds with activities against hematological malignancies, such as adenanthin, oridonin, gambogic acid and wogonoside, the identification of their targets, and their modes of actions.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Koehn FE, Carter GT. The evolving role of natural products in drug discovery. Nat Rev Drug Discov, 2005, 4: 206–220
Ji HF, Li XJ, Zhang HY. Natural products and drug discovery. Can thousands of years of ancient medical knowledge lead us to new and powerful drug combinations in the fight against cancer and dementia? EMBO Rep, 2009, 10: 194–200
Dias DA, Urban S, Roessner U. A historical overview of natural products in drug discovery. Metabolites, 2012, 2: 303–336
Chen J, Sun M, Wang X, Lu J, Wei Y, Tan Y, Liu Y, Gotz J, He R, Hua Q. The herbal compound geniposide rescues formaldehydeinduced apoptosis in N2a neuroblastoma cells. Sci China Life Sci, 2014, 57: 412–421
Newman DJ, Cragg GM. Natural products as sources of new drugs over the 30 years from 1981 to 2010. J Nat Prod, 2012, 75: 311–335
Ziegler S, Pries V, Hedberg C, Waldmann H. Target identification for small bioactive molecules: finding the needle in the haystack. Angew Chem Int Ed Engl, 2013, 52: 2744–2792
Doroghazi JR, Albright JC, Goering AW, Ju KS, Haines RR, Tchalukov KA, Labeda DP, Kelleher NL, Metcalf WW. A roadmap for natural product discovery based on large-scale genomics and metabolomics. Nat Chem Biol, 2014, 10: 963–968
Wang L, Chen G. Current advances in the application of proteomics in apoptosis research. Sci China Life Sci, 2011, 54: 209–219
Chen GQ, Zhang J, Zhao Q. Active compounds-based discoveries about the differentiation and apoptosis of leukemic cells. Chin Sci Bull, 2009, 54: 4094–4101
Wang Q, Cheng T. Evidences for mutations in the histone modifying gene SETD2 as critical drivers in leukemia development. Sci China Life Sci, 2014, 57: 944–946
Hamilton A, Gallipoli P, Nicholson E, Holyoake TL. Targeted therapy in haematological malignancies. J Pathol, 2010, 220: 404–418
Panjarian S, Iacob RE, Chen S, Engen JR, Smithgall TE. Structure and dynamic regulation of Abl kinases. J Biol Chem, 2013, 288: 5443–5450
Chereda B, Melo JV. Natural course and biology of CML. Ann Hematol, 2015, 94: S107–S121
Ben-Neriah Y, Daley GQ, Mes-Masson AM, Witte ON, Baltimore D. The chronic myelogenous leukemia-specific P210 protein is the product of the bcr/abl hybrid gene. Science, 1986, 233: 212–214
Yan H, Wang YC, Li D, Wang Y, Liu W, Wu YL, Chen GQ. Arsenic trioxide and proteasome inhibitor bortezomib synergistically induce apoptosis in leukemic cells: the role of protein kinase Cdelta. Leukemia, 2007, 21: 1488–1495
Meng L, Huang XJ. Fighting against hematological malignancy in china: from unique system to global impact. Sci China Life Sci, 2015, in press
Tallman MS. Acute promyelocytic leukemia. Best Pract Res Clin Haematol, 2014, 27: 1
Zhang XW, Yan XJ, Zhou ZR, Yang FF, Wu ZY, Sun HB, Liang WX, Song AX, Lallemand-Breitenbach V, Jeanne M, Zhang QY, Yang HY, Huang QH, Zhou GB, Tong JH, Zhang Y, Wu JH, Hu HY, de The H, Chen SJ, Chen Z. Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML. Science, 2010, 328: 240–243
Wei S, Kozono S, Kats L, Nechama M, Li W, Guarnerio J, Luo M, You MH, Yao Y, Kondo A, Hu H, Bozkurt G, Moerke NJ, Cao S, Reschke M, Chen CH, Rego EM, Lo-Coco F, Cantley LC, Lee TH, Wu H, Zhang Y, Pandolfi PP, Zhou XZ, Lu KP. Active Pin1 is a key target of all-trans retinoic acid in acute promyelocytic leukemia and breast cancer. Nat Med, 2015, 21: 457–466
Ito T, Handa H. Myeloid disease: another action of a thalidomide derivative. Nature, 2015, 523: 167–168
Teo SK, Stirling DI, Zeldis JB. Thalidomide as a novel therapeutic agent: new uses for an old product. Drug Discov Today, 2005, 10: 107–114
Kronke J, Udeshi ND, Narla A, Grauman P, Hurst SN, McConkey M, Svinkina T, Heckl D, Comer E, Li XY, Ciarlo C, Hartman E, Munshi N, Schenone M, Schreiber SL, Carr SA, Ebert BL. Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science, 2014, 343: 301–305
Lu G, Middleton RE, Sun H, Naniong M, Ott CJ, Mitsiades CS, Wong KK, Bradner JE, Kaelin WG, Jr. The myeloma drug lenalidomide promotes the cereblon-dependent destruction of ikaros proteins. Science, 2014, 343: 305–309
List A, Dewald G, Bennett J, Giagounidis A, Raza A, Feldman E, Powell B, Greenberg P, Thomas D, Stone R, Reeder C, Wride K, Patin J, Schmidt M, Zeldis J, Knight R. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med, 2006, 355: 1456–1465
List A, Kurtin S, Roe DJ, Buresh A, Mahadevan D, Fuchs D, Rimsza L, Heaton R, Knight R, Zeldis JB. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med, 2005, 352: 549–557
Krönke J, Fink EC, Hollenbach PW, MacBeth KJ, Hurst SN, Udeshi ND, Chamberlain PP, Mani DR, Man HW, Gandhi AK, Svinkina T, Schneider RK, McConkey M, Jaras M, Griffiths E, Wetzler M, Bullinger L, Cathers BE, Carr SA, Chopra R, Ebert BL. Lenalidomide induces ubiquitination and degradation of CK1alpha in del(5q) MDS. Nature, 2015, 523: 183–188
Morceau F, Chateauvieux S, Orsini M, Trecul A, Dicato M, Diederich M. Natural compounds and pharmaceuticals reprogram leukemia cell differentiation pathways. Biotechnol Adv, 2015, 33: 785–797
Robles-Fernandez I, Rodriguez-Serrano F, Alvarez PJ, Ortiz R, Rama AR, Prados J, Melguizo C, Alvarez-Manzaneda E, Aranega A. Antitumor properties of natural compounds and related molecules. Recent Pat Anticancer Drug Discov, 2013, 8: 203–215
Zhao Y, Niu XM, Qian LP, Liu ZY, Zhao QS, Sun HD. Synthesis and cytotoxicity of some new eriocalyxin B derivatives. Eur J Med Chem, 2007, 42: 494–502
Wang L, Li D, Wang C, Zhang Y, Xu J. Recent progress in the development of natural ent-kaurane diterpenoids with anti-tumor activity. Mini Rev Med Chem, 2011, 11: 910–919
Sun HD, Huang SX, Han QB. Diterpenoids from isodon species and their biological activities. Nat Product Rep, 2006, 23: 673–698
Gu ZM, Wu YL, Zhou MY, Liu CX, Xu HZ, Yan H, Zhao Y, Huang Y, Sun HD, Chen GQ. Pharicin B stabilizes retinoic acid receptor-alpha and presents synergistic differentiation induction with ATRA in myeloid leukemic cells. Blood, 2010, 116: 5289–5297
Xu HZ, Huang Y, Wu YL, Zhao Y, Xiao WL, Lin QS, Sun HD, Dai W, Chen GQ. Pharicin A, a novel natural ent-kaurene diterpenoid, induces mitotic arrest and mitotic catastrophe of cancer cells by interfering with BubR1 function. Cell Cycle, 2010, 9: 2897–2907
Jiang B, Yang H, Li ML, Hou AJ, Han QB, Wang SJ, Li SH, Sun HD. Diterpenoids from isodon adenantha. J Nat Prod, 2002, 65: 1111–1116
Liu CX, Yin QQ, Zhou HC, Wu YL, Pu JX, Xia L, Liu W, Huang X, Jiang T, Wu MX, He LC, Zhao YX, Wang XL, Xiao WL, Chen HZ, Zhao Q, Zhou AW, Wang LS, Sun HD, Chen GQ. Adenanthin targets peroxiredoxin I and IIto induce differentiation of leukemic cells. Nat Chem Biol, 2012, 8: 486–493
Liu CX, Zhou HC, Yin QQ, Wu YL, Chen GQ. Targeting peroxiredoxins against leukemia. Exp Cell Res, 2013, 319: 170–176
Schieber M, Chandel NS. ROS function in redox signaling and oxidative stress. Curr Biol, 2014, 24: R453–R462
Kang SW, Lee S, Lee EK. ROS and energy metabolism in cancer cells: alliance for fast growth. Arch Pharm Res, 2015, 38: 338–345
Wood ZA, Schroder E, Robin Harris J, Poole LB. Structure, mechanism and regulation of peroxiredoxins. Trends Biochem Sci, 2003, 28: 32–40
Dong T, Li C, Wang X, Dian L, Zhang X, Li L, Chen S, Cao R, Huang N, He S, Lei X. Ainsliadimer A selectively inhibits IKKalpha/beta by covalently binding a conserved cysteine. Nat Commun, 2015, 6: 6522
Ye ZW, Zhang J, Townsend DM, Tew KD. Oxidative stress, redox regulation and diseases of cellular differentiation. Biochim Biophys Acta, 2014, 1850: 1607–1621
Hou JK, Huang Y, He W, Yan ZW, Fan L, Liu MH, Xiao WL, Sun HD, Chen GQ. Adenanthin targets peroxiredoxin I/II to kill hepatocellular carcinoma cells. Cell Death Dis, 2014, 5: e1400
Yin QQ, Liu CX, Wu YL, Wu SF, Wang Y, Zhang X, Hu XJ, Pu JX, Lu Y, Zhou HC, Wang HL, Nie H, Sun HD, Chen GQ. Preventive and therapeutic effects of adenanthin on experimental autoimmune encephalomyelitis by inhibiting NF-kappaB signaling. J Immunol, 2013, 191: 2115–2125
Muchowicz A, Firczuk M, Chlebowska J, Nowis D, Stachura J, Barankiewicz J, Trzeciecka A, Klossowski S, Ostaszewski R, Zagozdzon R, Pu JX, Sun HD, Golab J. Adenanthin targets proteins involved in the regulation of disulphide bonds. Biochem Pharmacol, 2014, 89: 210–216
Soethoudt M, Peskin AV, Dickerhof N, Paton LN, Pace PE, Winterbourn CC. Interaction of adenanthin with glutathione and thiol enzymes: Selectivity for thioredoxin reductase and inhibition of peroxiredoxin recycling. Free Radic Biol Med, 2014, 77: 331–339
Siernicka M, Winiarska M, Bajor M, Firczuk M, Muchowicz A, Bobrowicz M, Fauriat C, Golab J, Olive D, Zagozdzon R. Adenanthin, a new inhibitor of thiol-dependent antioxidant enzymes, impairs the effector functions of human natural killer cells. Immunology, 2015, 146: 173–183
Li Y, Yin J, Li T, Huang S, Yan H, Leavenworth JM, Wang X. Natural killer cell based cancer immunotherapy: from basic biology to clinical application. Sci China Life Sci, 2015, in press
Margarucci L, Monti MC, Tosco A, Esposito R, Zampella A, Sepe V, Mozzicafreddo M, Riccio R, Casapullo A. Theonellasterone, a steroidal metabolite isolated from a theonella sponge, protects peroxiredoxin-1 from oxidative stress reactions. Chem Commun (Camb), 2015, 51: 1591–1593
Zhou GB, Chen SJ, Wang ZY, Chen Z. Back to the future of oridonin: again, compound from medicinal herb shows potent antileukemia efficacies in vitro and in vivo. Cell Res, 2007, 17: 274–276
Zhao Z, Chen Y. Oridonin, a promising antitumor natural product in the chemotherapy of hematological malignancies. Curr Pharm Biotechnol, 2014, 15: 1083–1092
Gao FH, Hu XH, Li W, Liu H, Zhang YJ, Guo ZY, Xu MH, Wang ST, Jiang B, Liu F, Zhao YZ, Fang Y, Chen FY, Wu YL. Oridonin induces apoptosis and senescence in colorectal cancer cells by increasing histone hyperacetylation and regulation of p16, p21, p27 and c-myc. BMC Cancer, 2010, 10: 610
Liu Z, Ouyang L, Peng H, Zhang WZ. Oridonin: targeting programmed cell death pathways as an anti-tumour agent. Cell Prolif, 2012, 45: 499–507
Li X, Wang J, Ye Z, Li JC. Oridonin up-regulates expression of P21 and induces autophagy and apoptosis in human prostate cancer cells. Int J Biol Sci, 2012, 8: 901–912
Ikezoe T, Chen SS, Tong XJ, Heber D, Taguchi H, Koeffler HP. Oridonin induces growth inhibition and apoptosis of a variety of human cancer cells. Int J Oncol, 2003, 23: 1187–1193
Wang MY, Lin C, Zhang TM. Cytokinetic effects of oridonin on leukemia l1210 cells. Zhongguo Yao Li Xue Bao, 1985, 6: 195–198
Wang MY, Lin C, Zhang TM. effects of oridonin on DNA, RNA and protein syntheses of leukemia l 1210 cells studied by autoradiography. Zhongguo Yao Li Xue Bao, 1987, 8: 164–165
Zhou GB, Kang H, Wang L, Gao L, Liu P, Xie J, Zhang FX, Weng XQ, Shen ZX, Chen J, Gu LJ, Yan M, Zhang DE, Chen SJ, Wang ZY, Chen Z. Oridonin, a diterpenoid extracted from medicinal herbs, targets AML1-ETO fusion protein and shows potent antitumor activity with low adverse effects on t(8;21) leukemia in vitro and in vivo. Blood, 2007, 109: 3441–3450
Zhen T, Wu CF, Liu P, Wu HY, Zhou GB, Lu Y, Liu JX, Liang Y, Li KK, Wang YY, Xie YY, He MM, Cao HM, Zhang WN, Chen LM, Petrie K, Chen SJ, Chen Z. Targeting of AML1-ETO in t(8;21) leukemia by oridonin generates a tumor suppressor-like protein. Sci Transl Med, 2012, 4: 127ra138
Ikezoe T, Yang Y, Bandobashi K, Saito T, Takemoto S, Machida H, Togitani K, Koeffler HP, Taguchi H. Oridonin, a diterpenoid purified from rabdosia rubescens, inhibits the proliferation of cells from lymphoid malignancies in association with blockade of the NF-kappa B signal pathways. Mol Cancer Ther, 2005, 4: 578–586
Li FF, Yi S, Wen L, He J, Yang LJ, Zhao J, Zhang BP, Cui GH, Chen Y. Oridonin induces NPM mutant protein translocation and apoptosis in NPM1c+ acute myeloid leukemia cells in vitro. Acta Pharmacol Sin, 2014, 35: 806–813
Gao F, Tang Q, Yang P, Fang Y, Li W, Wu Y. Apoptosis inducing and differentiation enhancement effect of oridonin on the all-trans-retinoic acid-sensitive and -resistant acute promyelocytic leukemia cells. Int J Lab Hematol, 2010, 32: e114–e122
Cao Y, Wei W, Zhang N, Yu Q, Xu WB, Yu WJ, Chen GQ, Wu YL, Yan H. Oridonin stabilizes retinoic acid receptor alpha through ROS-activated NF-kappaB signaling. BMC Cancer, 2015, 15: 248
Guo Y, Shan Q, Gong Y, Lin J, Yang X, Zhou R. Oridonin in combination with imatinib exerts synergetic anti-leukemia effect in Ph+ acute lymphoblastic leukemia cells in vitro by inhibiting activation of LYN/mTOR signaling pathway. Cancer Biol Ther, 2012, 13: 1244–1254
Li L, Yue GG, Pu JX, Sun HD, Fung KP, Leung PC, Han QB, Lau CB, Leung PS. Eriocalyxin B-induced apoptosis in pancreatic adenocarcinoma cells through thiol-containing antioxidant systems and downstream signalling pathways. Curr Mol Med, 2014, 14: 673–689
Gao FH, Liu F, Wei W, Liu LB, Xu MH, Guo ZY, Li W, Jiang B, Wu YL. Oridonin induces apoptosis and senescence by increasing hydrogen peroxide and glutathione depletion in colorectal cancer cells. Int J Mol Med, 2012, 29: 649–655
Dal Piaz F, Cotugno R, Lepore L, Vassallo A, Malafronte N, Lauro G, Bifulco G, Belisario MA, De Tommasi N. Chemical proteomics reveals HSP70 1A as a target for the anticancer diterpene oridonin in Jurkat cells. J Proteomics, 2013, 82: 14–26
Ye BX, Deng X, Shao LD, Lu Y, Xiao R, Liu YJ, Jin Y, Xie YY, Zhao Y, Luo LF, Ma S, Gao M, Zhang LR, He J, Zhang WN, Chen Y, Xia CF, Deng M, Liu TX, Zhao QS, Chen SJ, Chen Z. Vibsanin B preferentially targets HSP90beta, inhibits interstitial leukocyte migration, and ameliorates experimental autoimmune encephalomyelitis. J Immunol, 2015, 194: 4489–4497
Weng H, Huang H, Dong B, Zhao P, Zhou H, Qu L. Inhibition of miR-17 and miR-20a by oridonin triggers apoptosis and reverses chemoresistance by derepressing BIM-S. Cancer Res, 2014, 74: 4409–4419
Zhou ZT, Wan JW. Phase I human tolerability trial of gambogic acid. Chin J New Drugs, 2007, 1: 679–682
Shi XP, Jin YL, Cheng C, Zhang H, Zou WY, Zheng Q, Lu ZZ, Chen Q, Lai YR, Pan JX. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation. Clin Cancer Res, 2009, 15: 1686–1697
Shi X, Chen X, Li X, Lan X, Zhao C, Liu S, Huang H, Liu N, Liao S, Song W, Zhou P, Wang S, Xu L, Wang X, Dou QP, Liu J. Gambogic acid induces apoptosis in imatinib-resistant chronic myeloid leukemia cells via inducing proteasome inhibition and caspase-dependent Bcr-Abl downregulation. Clin Cancer Res, 2014, 20: 151–163
Cvetkovic RS, Perry CM. Rituximab: a review of its use in non-Hodgkin’s lymphoma and chronic lymphocytic leukaemia. Drugs, 2006, 66: 791–820
Shi X, Lan X, Chen X, Zhao C, Li X, Liu S, Huang H, Liu N, Zang D, Liao Y, Zhang P, Wang X, Liu J. Gambogic acid induces apoptosis in diffuse large B-cell lymphoma cells via inducing proteasome inhibition. Sci Rep, 2015, 5: 9694
Pandey MK, Sung B, Ahn KS, Kunnumakkara AB, Chaturvedi MM, Aggarwal BB. Gambogic acid, a novel ligand for transferrin receptor, potentiates tnf-induced apoptosis through modulation of the nuclear factor-kappaB signaling pathway. Blood, 2007, 110: 3517–3525
Yi T, Yi Z, Cho SG, Luo J, Pandey MK, Aggarwal BB, Liu M. Gambogic acid inhibits angiogenesis and prostate tumor growth by suppressing vascular endothelial growth factor receptor 2 signaling. Cancer Res, 2008, 68: 1843–1850
Li XF, Liu ST, Huang HB, Liu NN, Zhao C, Liao SY, Yang CS, Liu YR, Zhao CG, Li SJ, Lu XY, Liu CJ, Guan LX, Zhao K, Shi XQ, Song WB, Zhou P, Dong XX, Guo HP, Wen GM, Zhang CG, Jiang LL, Ma NF, Li B, Wang SQ, Tan H, Wang XJ, Dou QP, Liu JB. Gambogic acid is a tissue-specific proteasome inhibitor in vitro and in vivo. Cell Rep, 2013, 3: 211–222
da Fonseca PC, He J, Morris EP. Molecular model of the human 26S proteasome. Mol Cell, 2012, 46: 54–66
He L, Lu N, Dai Q, Zhao Y, Zhao L, Wang H, Li Z, You Q, Guo Q. Wogonin induced G1 cell cycle arrest by regulating Wnt/beta-catenin signaling pathway and inactivating CDK8 in human colorectal cancer carcinoma cells. Toxicology, 2013, 312: 36–47
Chirumbolo S. Anticancer properties of the flavone wogonin. Toxicology, 2013, 314: 60–64
Han J, Ye M, Xu M, Sun J, Wang B, Guo D. Characterization of flavonoids in the traditional chinese herbal medicine-huangqin by liquid chromatography coupled with electrospray ionization mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci, 2007, 848: 355–362
Lopez-Lazaro M. Distribution and biological activities of the flavonoid luteolin. Mini Rev Med Chem, 2009, 9: 31–59
Yanagihara N, Zhang H, Toyohira Y, Takahashi K, Ueno S, Tsutsui M, Takahashi K. New insights into the pharmacological potential of plant flavonoids in the catecholamine system. J Pharmacol Sci, 2014, 124: 123–128
Li-Weber M. New therapeutic aspects of flavones: the anticancer properties of scutellaria and its main active constituents wogonin, baicalein and baicalin. Cancer Treatment Rev, 2009, 35: 57–68
Lee WR, Shen SC, Lin HY, Hou WC, Yang LL, Chen YC. Wogonin and fisetin induce apoptosis in human promyeloleukemic cells, accompanied by a decrease of reactive oxygen species, and activation of caspase 3 and Ca2+-dependent endonuclease. Biochem Pharmacol, 2002, 63: 225–236
Huang ST, Wang CY, Yang RC, Chu CJ, Wu HT, Pang JH. Wogonin, an active compound in Scutellaria baicalensis, induces apoptosis and reduces telomerase activity in the HL-60 leukemia cells. Phytomedicine, 2010, 17: 47–54
Hu C, Xu M, Qin R, Chen W, Xu X. Wogonin induces apoptosis and endoplasmic reticulum stress in HL-60 leukemia cells through inhibition of the PI3K-AKT signaling pathway. Oncol Rep, 2015, 33: 3146–3454
Himeji M, Ohtsuki T, Fukazawa H, Tanaka M, Yazaki S, Ui S, Nishio K, Yamamoto H, Tasaka K, Mimura A. Difference of growth-inhibitory effect of scutellaria baicalensis-producing flavonoid wogonin among human cancer cells and normal diploid cell. Cancer Lett, 2007, 245: 269–274
Baumann S, Fas SC, Giaisi M, Muller WW, Merling A, Gulow K, Edler L, Krammer PH, Li-Weber M. Wogonin preferentially kills malignant lymphocytes and suppresses T-cell tumor growth by inducing PLCgamma1- and Ca2+-dependent apoptosis. Blood, 2008, 111: 2354–2363
Polier G, Ding J, Konkimalla BV, Eick D, Ribeiro N, Kohler R, Giaisi M, Efferth T, Desaubry L, Krammer PH, Li-Weber M. Wogonin and related natural flavones are inhibitors of CDK9 that induce apoptosis in cancer cells by transcriptional suppression of Mcl-1. Cell Death Disease, 2011, 2: e182
Polier G, Giaisi M, Kohler R, Muller WW, Lutz C, Buss EC, Krammer PH, Li-Weber M. Targeting CDK9 by wogonin and related natural flavones potentiates the anti-cancer efficacy of the Bcl-2 family inhibitor ABT-263. Int J Cancer, 2015, 136: 688–698
Lin CC, Lin JJ, Wu PP, Lu CC, Chiang JH, Kuo CL, Ji BC, Lee MH, Huang AC, Chung JG. Wogonin, a natural and biologically-active flavonoid, influences a murine WEHI-3 leukemia model in vivo through enhancing populations of T- and B-cells. In Vivo, 2013, 27: 733–738
Zhang HW, Yang Y, Zhang K, Qiang L, Yang L, Hu Y, Wang XT, You QD, Guo QL. Wogonin induced differentiation and G1 phase arrest of human U-937 leukemia cells via PKCdelta phosphorylation. Eur J Pharmacol, 2008, 591: 7–12
Hollman PC, Katan MB. Absorption, metabolism and health effects of dietary flavonoids in man. Biomed Pharmacother, 1997, 51: 305–310
Lim BO. Effects of wogonin, wogonoside, and 3, 5, 7, 2', 6'- pentahydroxyflavone on chemical mediator production in peritoneal exduate cells and immunoglobulin E of rat mesenteric lymph node lymphocytes. J Ethnopharmacol, 2003, 84: 23–29
Chen Y, Lu N, Ling Y, Gao Y, Wang L, Sun Y, Qi Q, Feng F, Liu W, You Q, Guo Q. Wogonoside inhibits lipopolysaccharide-induced angiogenesis in vitro and in vivo via toll-like receptor 4 signal transduction. Toxicology, 2009, 259: 10–17
Chen Y, Hui H, Yang H, Zhao K, Qin Y, Gu C, Wang X, Lu N, Guo Q. Wogonoside induces cell cycle arrest and differentiation by affecting expression and subcellular localization of PLSCR1 in AML cells. Blood, 2013, 121: 3682–3691
Huang Y, Zhao Q, Chen GQ. Phospholipid scramblase 1. Sheng Li Xue Bao, 2006, 58: 501–510
Zhao KW, Li X, Zhao Q, Huang Y, Li D, Peng ZG, Shen WZ, Zhao J, Zhou Q, Chen Z, Sims PJ, Wiedmer T, Chen GQ. Protein kinase cdelta mediates retinoic acid and phorbol myristate acetate-induced phospholipid scramblase 1 gene expression: its role in leukemic cell differentiation. Blood, 2004, 104: 3731–3738
Zhao KW, Li D, Zhao Q, Huang Y, Silverman RH, Sims PJ, Chen GQ. Interferon-alpha-induced expression of phospholipid scramblase 1 through STAT1 requires the sequential activation of protein kinase Cdelta and JNK. J Biol Chem, 2005, 280: 42707–42714
Li Y, Rogulski K, Zhou Q, Sims PJ, Prochownik EV. The negative c-Myc target onzin affects proliferation and apoptosis via its obligate interaction with phospholipid scramblase 1. Mol Cell Biol, 2006, 26: 3401–3413
Wu SF, Huang Y, Hou JK, Yuan TT, Zhou CX, Zhang J, Chen GQ. The downregulation of onzin expression by PKCepsilon-ERK2 signaling and its potential role in AML cell differentiation. Leukemia, 2010, 24: 544–551
Kodigepalli KM, Bowers K, Sharp A, Nanjundan M. Roles and regulation of phospholipid scramblases. FEBS Lett, 2015, 589: 3–14
Huang Y, Zhao Q, Zhou CX, Gu ZM, Li D, Xu HZ, Wiedmer T, Sims PJ, Zhao KW, Chen GQ. Antileukemic roles of human phospholipid scramblase 1 gene, evidence from inducible PLSCR1- expressing leukemic cells. Oncogene, 2006, 25: 6618–6627
Zhou Q, Ben-Efraim I, Bigcas JL, Junqueira D, Wiedmer T, Sims PJ. Phospholipid scramblase 1 binds to the promoter region of the inositol 1, 4, 5-triphosphate receptor type 1 gene to enhance its expression. J Biol Chem, 2005, 280: 35062–35068
Mikoshiba K. IP3 receptor/Ca2+ channel: from discovery to new signaling concepts. J Neurochem, 2007, 102: 1426–1446
Acharya JK, Jalink K, Hardy RW, Hartenstein V, Zuker CS. InsP3 receptor is essential for growth and differentiation but not for vision in Drosophila. Neuron, 1997, 18: 881–887
Harvey AL, Edrada-Ebel R, Quinn RJ. The re-emergence of natural products for drug discovery in the genomics era. Nat Rev Drug Discov, 2015, 14: 111–129
Author information
Authors and Affiliations
Corresponding author
Additional information
This article is published with open access at link.springer.com
Rights and permissions
Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0), which permits use, duplication, adaptation, distribution, and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
About this article
Cite this article
Xu, Y., Liu, J., Wu, Y. et al. Natural products against hematological malignancies and identification of their targets. Sci. China Life Sci. 58, 1191–1201 (2015). https://doi.org/10.1007/s11427-015-4922-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11427-015-4922-4